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ABSTRACT  
The synthetic feasibility of any compound library used for virtual screening is critical to the drug 
discovery process. TIN, a recursive acronym for „TIN Is Not commercial‟, is a virtual combinatorial 
database enumeration of diversity-orientated multicomponent syntheses (MCR).  Using a „one-pot‟ 
synthetic technique, 12 unique small molecule scaffolds were developed, predominantly styrylisoxazoles 
and bis-acetylenic ketones, with extensive derivatization potential. Importantly, the scaffolds were 
accessible in a single operation from commercially available sources containing R-groups which were 
then linked combinatorially. This resulted in a combinatorial database of over 28 million product 
structures, each of which is synthetically feasible. These structures can be accessed through a free web-
based 2D structure search engine, or download in SMILES, MOL2 and SDF formats. Subsets include a 
10% diversity subset, a drug-like subset and a lead-like subset that are also freely available for download 
and virtual screening (http://mmg.rcsi.ie:8080/tin).   
 
KEYWORDS 
Chemoinformatics, combinatorial chemistry, multicomponent synthesis, diversity orientated synthesis, 
drug discovery, derivatization, database, structure search, free access. 
 
BRIEFS 
Enumeration of a virtual combinatorial compound library of 28m small molecules that can be 
synthesized using simple multicomponent methods.  
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INTRODUCTION 
Virtual Screening (VS) is a viable and rapid method to search for ligands and antagonists of novel 
target proteins.
1-3
 While the costly high throughput screening (HTS) of hundreds of thousands of 
synthesized compounds remains the predominant method used by the pharmaceutical industry, VS is 
steadily growing in importance and is increasingly being used to support drug discovery efforts.
4-6
 Large 
databases of millions of compounds can be screened relatively rapidly using docking software, 
pharmacophore based substructure matching, or descriptor based filtering rules.
5
 Ligand databases 
include collections of commercially available molecules such as the ZINC database compiled by Irwin 
and Shoichet,
7
 or virtual representations of either 'in house' compound collections or commercially 
available compound libraries. Top scoring hits are then purchased and tested in vitro and may yield lead 
compounds effective against the target protein.   
Development of the lead compound into a drug candidate may, however, be limited by synthetic 
complexity which reduces the scope for derivatization of these lead compounds. Derivative synthesis 
involving numerous steps, some or many of which may be patented, could result in poor yields and 
unpatentable drug candidates. This may necessitate the redesign of the synthetic route with concomitant 
delays in the drug discovery pipeline. Furthermore, the synthesis pathway may limit the available choice 
of derivatives due to incompatible side reactions. Synthetic feasibility of the compound library is thus 
critical to the drug discovery process.  
A few years ago, Adamo‟s group initiated a program of research aimed at generating chemical 
diversity through multi-component reactions. This approach to the development of diversity-oriented 
syntheses was based on the generation of building blocks that contain multiple functionalities which 
could be selectively reacted. Therefore, it was hypothesised that a scaffold containing a number of 
functionalities m which could be selectively reacted through a number of n reactions would have 
generated diversity in D = mn directions.
8
 This study generated several one-pot multicomponent 
reactions, the synthetic details of which were described in previous papers.
8-13
 Diversity is achieved by 
substituting each of three or four substituents at one time and keeping the synthetic strategy already 
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optimized constant. In this fashion synthesis of opportunely modified structures could be achieved 
within hours/days instead of weeks/months. While this is clearly a rich source of structural diversity, the 
technology remains in the domain of the skilled medicinal chemist and is not readily available for 
chemoinformatics exploration. We have thus enumerated a significant fraction of the possible 
derivatives that can be constructed using each of numerous multicomponent synthesis methods, resulting 
in over 28 million virtual compounds. It is important to note that each of these 28 million compounds is 
theoretically synthetically feasible, as examples of each scaffold structure have been synthesized, 
characterized, and described in the literature.
8-13
 To the best of our knowledge, this is the first publicly 
available database of synthetically feasible combinatorial compounds that can be produced using the 
multicomponent „one-pot‟ synthesis method (http://mmg.rcsi.ie:8080/tin). A number of subsets („drug-
like‟, „lead-like‟ and 10% diversity) are available for download and incorporation into docking or virtual 
screening studies, while the remaining analogues are available through a web based search engine. 
Synthetically feasible analogues of lead compounds can thus be found using the 2D structural search. 
This will provide researchers with a set of readily synthesizable derivatives for lead optimization. 
 
MATERIALS AND METHODS 
Software used. The modelling program used for preparation of virtual molecular structures was MOE 
(Molecular Operating Environment) from the Chemical Computing Group, Montreal, Canada. The 2D 
search is performed using OpenBabel (www.openbabel.org). Statistics were prepared using a MySQL 
(www.mysql.com) database of the full library on an Ubuntu Linux server (www.ubuntu.com), and Toad 
(www.toadsoft.com) as the MS Windows interface. The website was programmed in Java 
(www.java.com), using NetBeans IDE (www.netbeans.org). Structural fingerprints for comparison to 
the ZINC database were generated using the Chemistry Development Kit java package 
(http://sourceforge.net/projects/cdk/).
14
 
Synthesis of scaffolds MA01-MA21: The basic scaffold structure of each synthetic route is shown in 
Figure 1, while Schemes 1-12 provide more detail regarding the possible permutations of these 
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scaffolds. Compounds MA01 (Scheme 1) were obtained by reacting equimolar amounts of 3,5-
dimethyl-4-nitroisoxazole (Isi), an aromatic aldehyde (Ald), a -diketone (K) in the presence and 
hydrazine or hydroxylamine (X) in the presence of piperidine followed by treatment with aqueous 
sodium hydroxide.
12
 Compounds MA02 (Scheme 2) were obtained by reacting equimolar amounts of 
2,5-dimethyl-4-nitroisoxazole (Isi), an aromatic aldehyde (Ald), a -diketone (K) and hydrazine or 
hydroxylamine (X) in the presence of piperidine.
12
 Compounds MA03 (Scheme 3) were obtained by 
reacting MA02 with SnCl2 followed by treatment with an in situ generated acyl chloride. This synthesis 
is as yet unreported and will be described elsewhere. Compounds MA04 (Scheme 4) were obtained by 
reacting equimolar amounts of 3,5-dimethyl-4-nitroisoxazole (Isi), an aromatic aldehyde (Ald) and a -
diketone (K) in the presence of substoichiometric amounts of piperidine base.
8
 Compounds MA05 
(Scheme 5) were obtained by reacting equimolar amounts of 3,5-dimethyl-4-nitroisoxazole (Isi), an 
aromatic aldehyde (Ald) and a -diketone (K) in the presence of two equivalents of piperidine base.8 
Compounds MA06 (Scheme 6) were obtained by reacting equimolar amounts of 3,5-dimethyl-4-
nitroisoxazole (Isi), an aromatic aldehyde (Ald) and a -diketone (K) in the presence of 
substoichiometric amounts of piperidine base.
11
 Compounds MA07 (Scheme 7) were obtained in two 
steps reacting equimolar amounts of 3,5-dimethyl-4-nitroisoxazole (Isi), an aromatic aldehyde (Ald), 
and a -diketone (K) in the presence of substoichiometric amounts of piperidine base, then adding DCC 
and amine. This synthesis is unreported and will be described elsewhere. Compounds MA08 (Scheme 8) 
were obtained in two steps by reacting equimolar amounts of 3,5-dimethyl-4-nitroisoxazole (Isi), an 
aromatic aldehyde (Ald), and diethyl malonate (K) in the presence of substoichiometric amounts of 
piperidine base, then treating the resulting adduct with dilute HCl and excess SnCl2.
11
 Compounds 
MA11 (Scheme 9) were obtained in two steps by reacting equimolar amounts of 3,5-dimethyl-4-
nitroisoxazole (Isi), an aromatic aldehyde (Ald), and nitromethane (K) in the presence of 
substoichiometric amounts of piperidine base, then treating the resulting adduct with dilute HCl and 
excess SnCl2
13
. Compounds MA16 (Scheme 10) were obtained by reacting bis acetylenic ketones with 
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equimolar amounts of an opportune enamine.
9
 Compounds MA20 and MA21 (Scheme 11 and 12) were 
prepared by reaction of bis acetylenic ketones and an opportunely substituted Boc-amidrazone in the 
presence of excess trifluoroacetic anhydride.
10
 
Creating Constituent Databases. Creation and collation of initial constituent databases was 
performed manually to prevent common automation problems occurring early in the database creation 
process. Compounds which were identified as possible constituents in a scaffold-based molecule in the 
initial search were then searched for by product number in the electronic Sigma-Aldrich structure data 
file (SDF) catalogue. When a product was matched, constituent molecules were separated based on 
specific substructures, resulting in 11 databases (see Table 1).  The Sigma SD files were planar and did 
not account for chirality.  Hydrogen atoms were added where necessary and compounds allowed to relax 
using the steepest decent algorithm and the MMFF94x forcefield with default settings in MOE. 
Alternative, more efficient, options for 3D topology creation that are free for academia include the 
CORINA
15
 and OMEGA
16
 systems. To ensure correct stereochemistry we manually checked each 
molecule. If necessary, a molecule‟s chirality was changed to reflect that described in the full compound 
name. Where only racemic mixtures were available, or the full name could not be established, all 
combinations of chirality were manually stored in the database under the same name and catalogue 
number but with each set of chiral combination noted. All molecules with more than four chiral centers 
were discarded. Occasionally the structure needed to be reconstructed in MOE using the 2D drawing on 
the Sigma-Aldrich website as a guide. Where the product number differed from that on the website, this 
was updated in the constituent database to reflect the website nomenclature. 
Creating Scaffold Databases. Numerous scaffolds were created on the basis of this synthetic 
technique with a high level of variety in their basic structure, as seen in Schemes 1-12. Various elements 
of the scaffold structure are variable while the basic structure generally remains consistent. This means 
that for every basic scaffold there are a number of different second generation scaffolds which can be 
created from it. This variety allows for even greater combinatorial expansion when combined with 
reagent (R-group) databases. Each scaffold possibility was constructed using MOE and then assigned a 
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name according to a specific nomenclature described in Schemes 1-12 and described in more detail here. 
Each scaffold has a basic structure which is indicated by the title MA00, where 00 represents a number 
which defines the synthetic route. K groups (depicted in blue in the Schemes) are represented by K00, 
and X groups (depicted in red or green) are represented by X00. For example, Scaffold MA01 has 
fifteen different second generation scaffolds which are all defined by the combination of MA, K, and X 
groups present in the title. Therefore, MA01K02X03 indicates that this scaffold is made up of the basic 
parent scaffold of MA01, its variable R-groups which form a backbone are made up of -CF3 groups, and 
the N-X group is in this case a methyl hydrazine (N-N-CH3). If, as in Scaffold MA02, there was more 
than one X group present, the X groups were differentiated as being either XA00 or XB00. Which group 
is considered A and B is noted in the Schemes. Individual databases of both X and K groups were also 
created to serve as a key marrying structure to name in MySQL backtracking of the component parts. 
Finally, each scaffold has an attachment site to which a subset of compounds with specific reactive 
groups will bind. For example, MA02 molecules bind to aldehydes, as can be seen in Scheme 2. This 
was represented on the virtual scaffold as a „port‟ with which an R-group molecule could later link. In 
some instances, for example MA01, some scaffolds have more than one „port‟, often for different types 
of molecules. In this instance again, the „ports‟ are differentiated as A1-An, where n represents an 
integer; these numbers must be labeled consecutively.  Because of the large number of scaffold 
permutations associated with MA03 (75 unique descendant scaffolds), the MA03 database was split into 
8 different databases called MA03(a)-(h). MA03(h) database contains only 5 scaffolds while the others 
contain ten. All scaffolds used can be downloaded from the TIN website (http://mmg.rcsi.ie:8080/tin). 
Clipping R-Groups. Abbreviations used: aldehyde (Ald); alcohol (Alch), carboxylic acids (Ac), 
amines (NHAmi). Because each compound within the constituent database was screened initially by 
chemists with the one-pot synthesis in mind, each constituent was grouped to need the same „clip‟ to 
prepare for linking with a scaffold. For example, scaffold MA01 requires an aldehyde group which is 
seen in the resulting molecule as simply the Ald constituent as the carbonyl element of the aldehyde is 
removed in the chemical process. Therefore, when preparing the Ald databases of constituent molecules 
 8 
to become a database of R-groups ready for combinatorial linkage, a „clip‟ removed the carbonyl group 
and replaced it with a „port‟ which is ready to dock with the scaffold resulting in the final product. Ports 
on the R-Groups are labeled with A0. Each „clip‟ was designed with the synthetic process in mind so 
that the final virtual R-group, when linked, would be representative of the final product of chemical 
synthesis. These „clips‟ are represented as SMILES strings in Table 1. Each clip was then assigned a 
unique name and number which allow for easy identification based on its chemical properties. For 
example, an aliphatic alcohol present in the Alch database would be named Alch_naro_nnnn, where n 
is an integer. This unique tag was linked to the R-group so that in subsequent molecular construction, it 
would always be present in the name of the final molecule, indicating which R-group was involved in 
making that product. The alcohol (Alch) subset was further divided into either phenols (Alch-aro) or 
aliphatic alcohols (Alch-naro), each of which were clipped to remove either a single hydrogen atom or 
the whole hydroxyl group. Only aromatic aldehydes were included in the aldehyde group (Ald). 
Carboxylic acids were subdivided into aromatic (Ac-aro) and aliphatic (Ac-naro) groups. Amine groups 
(NHAmi) were also divided into aromatic amines (NHAmi_aromatic) and the remainder 
(NHAmi_naromatic), both of which were further subdivided into either primary (-NH2) or secondary (-
NH) amines. 
Combinatorial Linking of R-groups to Scaffolds. By this point, both the scaffolds and the 
constituent R-groups have a „port‟ with which they are able to link; combining to form a single virtual 
molecule. Combinatorial linking was done using the Quasar:Combigen function in MOE. For each 
linking process, a log file detailing any errors was generated. If possible, all errors were corrected 
manually, otherwise the compound was deleted.  
Characterizing Output Databases. With construction complete, each output database was subjected 
to a variety of refinements. Each entry within each database was assigned a unique tag of 
RCSI_nnnnnnnn, where n is an integer. This tag was added to the original name of the molecule which 
consisted of the scaffold name and R-group identifying tags. Each database was then subjected to a 
steepest decent energy minimization process using the MMFF94x forcefield with default settings and 
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the addition of hydrogens where necessary.  This was done using in parallel the SMP function and MOE 
batch mode on six Dell Dual Xeon Pentium 6 machines with 2Mb RAM, each operating Linux RedHat.  
Molecular descriptors (listed in Supplementary Table S1) were then calculated for each output 
molecule. This descriptor calculation was done using functions in MOE's QuaSAR_Descriptor function 
in MOE/Batch. All the data are supplied in the download files. The descriptors were used to calculate 
the Lipinski „drug-like‟17, 18 and Oprea „lead-like‟ rules,19 depicted with a binary „1‟ or „0‟. In addition, 
substructure diversity selection was used to provide users with a smaller 10% diversity subset. All 
virtual molecules are available for download (in SMILES format only) and include the descriptor 
calculations.  
The potential energy was calculated as a final check of the MOE „minimize‟ function to ensure 
reasonable structural poses were produced. Any particularly high energy molecules were inspected 
manually for mistakes in construction and were corrected manually.  
As a final step, each database was exported into three commonly used formats: SDF, MOL2, and 
ASCII (exported as a TXT file), in addition to the MDB format specific to MOE. For internal use, the 
resulting SMILES strings are stored in a MySQL database allowing for standard Structured Query 
Language (SQL) searches throughout the collated database internally and as a basis for web-server 
integration. 
Structural Fingerprint Generation. To compare the structural diversity of TIN with the ZINC 
database, subsets of each database were randomly selected. A pre-prepared ZINC subset of purchasable 
compounds (#6), that differ from the rest by a Tanimoto cutoff score of 60%, was downloaded. This 
consisted of 10,082 compounds in SMILES format. 11,000 structures from the 10% diversity subset of 
TIN were randomly selected to give a representative group of molecules to compare to the ZINC subset. 
MOE was used to generate initial 3D structures for each molecule. A short java programme was written 
to calculate the CDK structural fingerprints
14
 for each molecule, and sum the occurrence of each 
fingerprint for plotting. 
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OpenBabel SMILES searching. The full TIN database can be searched on the „Search TIN‟ web 
page tab using the Java Molecular Editor kindly donated by Peter Ertl (Novartis). Alternatively, a TIN 
compound can be used as input by typing the compound number (prefixed with RCSI_) in the box 
provided. Each of these methods inserts a SMILES string in the search input box, which can also be 
loaded directly with a SMILES sting. After setting the search criteria (Tanimoto similarity score, 
substructure search, etc), the search starts an OpenBabel command that searches an indexed form of the 
full TIN database in SDF format (~220 GB file). As this takes a number of hours, the user can logout 
and will be notified by email when the output files are ready. These are stored in the „My Results‟ 
section with a unique file name created from the „search description‟ input. 
TIN component parts search. Once the user has selected the TIN compounds they are interested in 
synthesizing, either through screening the diversity subset or searching the whole dataset using the 
browser, one can then deconstruct the final synthetic products into their substituent starting materials. 
These starting materials can all be purchased directly from the supplier, in this case we used Sigma-
Aldrich, and the required TIN product synthesized using the chemistry detailed in the methods section 
and outlined in Schemes 1-12.  
On the „Synthesis‟ page, one can enter TIN codes (in the form RCSI_nnnnnnnn) in the search box 
provided. The output appears on the page in table format which includes the following columns; „Sort 
Order‟, keycode for the search; „RCSI Identifier‟, TIN code number; „Scaffold Template‟, core scaffold 
type;  „Scaffold‟, full scaffold name;  „Scaffold SMILES‟, full scaffold structure;  „compound SMILES‟, 
reagent structure; „compound weight‟, reagent weight; „Ports‟, position of port at which R-group is 
attached; „RGroups‟, name of side chain or R-group at specific port; „RGroup SMILES‟, side chain/R-
group compound structure at specific port; „RGroups chirality‟, up to 4 chiral centers were enumerated 
where the description was not clear; „RGroup Catalog Number‟, supplier catalogue number; „RGroup 
Supplier‟, supplier name. Users can then order the compounds directly from the supplier and synthesize 
the compound using the chemistry outlined and reference in the methods.  
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RESULTS AND DISCUSSION 
TIN aims, as ZINC does, to provide a straightforward way for users to access a large database of novel 
compounds. Using a „one-pot‟ synthetic technique, the combination of unique scaffolds and 
commercially available compound constituents from the Sigma-Aldrich catalogue, a database of novel 
synthetic compounds has been constructed. The TIN database is a collection of 28,473,744 virtual 
compounds, comprising over 220 GB of data in SDF format. Descriptive properties that define drug-like 
and lead-like compounds are present for all compounds allowing the user to independently search 
according to these subset properties or to sort databases according to these properties. Of the 28 million 
compounds, 5,080,762 (17.8%) are considered „drug-like‟ (Figures 2, 3, 4) and 1,731,331 (6.1%) are 
considered „lead-like‟. 
To further explore the structural diversity of the TIN database, structural fingerprints were identified 
in random subsets of both the TIN and ZINC databases. This fingerprint comprises 307 bits, each 
representing a discrete substructure. A pre-prepared diverse subset of 10,082 ZINC compounds was 
downloaded, and this was compared to 11,000 compounds chosen at random from the 10% diversity 
subset of TIN. A table describing the substructure SMARTS pattern of each fingerprint bit, as well as 
how many molecules from TIN and ZINC contained the substructure is included in Supplementary 
Table S2.  
Out of the 307 fingerprint substructure features, 209 appear in at least one ZINC molecule, and 104 
appear at least once in TIN. 102 of these features are common to at least one molecule from ZINC and 
TIN, while TIN contains two substructures that do not appear in ZINC, and ZINC contains 107 
substructures that do not appear in TIN. The distribution of fingerprints is shown in Figure 5. Each point 
in the figure represents a single substructure feature. It is clear that TIN shares about half the 
substructure fingerprints with ZINC, with a broadly similar distribution. Fingerprints lying along the x-
axis are those fingerprints in ZINC which do not occur in TIN. These comprise about half of the total 
fingerprint substructures contained in ZINC. Referring to Supplementary Table S2, the bulk of the 
features in ZINC that do not exist in TIN relate to various phosphorus, sulfur, and halogen containing 
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groups. However, phosphorus and halogen containing groups are reactive functional groups which may 
not be desirable from a medicinal chemistry point of view. 
The large size of the TIN database restricts online downloading of the full dataset in 3D format, but all 
28 million molecules are freely available for download in isomeric SMILES format. A smaller diversity 
subset (10%) was created and is available for download in SDF, MOL2, MDB and SMILES formats. 
„Lead-like‟ and „drug-like‟ subsets are also freely available for download in SDF, MOL2, MDB and 
SMILES formats. Once these have been used in virtual screening studies, it is envisaged that researchers 
will synthesize the hit compounds, and test them in vitro for effectivity.  
The TIN website also has a web-based application which allows users to search for molecules similar 
to the input molecule. Once lead small molecule inhibitors are established, the full TIN database can be 
searched for readily synthesizable derivatives using the JME molecule editor and the OpenBabel search 
function. These derivatives can then also be synthesized and screened, potentially yielding novel 
therapeutically useful drugs. 
TIN is a user-friendly public access database that provides a comprehensive search of small molecules 
available through multicomponent synthesis methods. Users are able to search the TIN database based 
on a variety of criteria; (i) diversity subset databases that contain a representative 10% of each scaffold 
database are available for ready download, (ii) drug-like compounds that obey Lipinski‟s „Rule-of-Five‟, 
(iii) smaller lead-like compounds, or (iv) all compounds (although this is only available in SMILES 
format due to the data transfer limitations. The issue of reducing the size of chemical space by excluding 
possible solutions is addressed by allowing TIN to be fully searchable; the structure based searches 
performed by users allow for full exploration of the entire collection of molecules and understanding of 
all TIN's molecular structures. Thus if a „hit‟ is found using the 10% diversity subset, the remaining 
„near neighbors‟ (that were filtered out) can now be accessed using the structure-based search engine. 
Each molecule is available for download in a variety of formats allowing for use in a variety of 
molecular modelling programs.  
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TIN is a sizable database containing a high number of unique molecules which satisfy „drug-like‟ and 
„lead-like‟ properties all of which are theoretically synthesizable. The open access nature of this large 
resource will hopefully facilitate further research from a variety of sectors in virtual screening and future 
drug design and development.  
To investigate how successfully the building blocks of the TIN database have been shown to act 
against protein targets in vitro, a substructure search for each of the 12 substructure scaffolds was 
carried out on the open-access ChEMBL
20
 and PubChem
21
 databases, which contain data on the 
biological activity of small molecules. The results are summarized in Table 2. This shows that a total of 
1,403 molecules containing TIN substructures have been found, with 37 experimentally validated 
activities against 18 protein targets (not including possible duplicates between databases). This indicates 
that there is potential for finding bioactive compounds within TIN. However, considering that TIN itself 
consists of over 28 million compounds, finding only 1,403 tested compounds in publically available 
databases indicates that TIN represents a relatively unexplored region of the chemical space.  
Recent analysis of modern patenting trends by the four largest pharmaceutical companies has shown a 
trend towards increasing hydrophobicity,
17
 and this is likely to result in higher attrition in late-stage 
clinical testing. Similarly, GlaxoSmithKline have recently made available the results of their anti-
malarial high throughput screening assays, in which they found a median molecular weight of 446 Da 
for active compounds.
22
 By the nature of the conjugated styrylisoxazole ring centre scaffold, the TIN 
database contains a significant proportion of highly hydrophobic molecules which fail the Lipinski Rule-
of-Five criteria (Figure 2). This is clearly inconsistent with the aim of the TIN database, namely the 
identification and development of novel pharmaceutical drugs. However, the widened scope of 
compounds considered a lead worthy of patent protection by „big pharma‟,17 coupled with large average 
size of anti-malarial hits found by GSK, implies that the TIN database should still hold valuable starting 
leads and novel scaffolds. Furthermore, the versatility of the multicomponent synthesis allows one to 
readily improve polarity and drug-likeness by replacing components with more polar analogues. A 
simple WWW-based structure search of the lead compound will output all possible analogues in TIN, 
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which can easily be sorted for non-violation of Lipinski‟s rules of five (where „lip_druglike‟ = 1), thus 
returning the user to more useful, low lipophilicity, chemical space.
17
  
To illustrate the potential utility of the TIN database, we searched it for compounds structurally 
similar to the anti-thrombotic platelet integrin inhibitor Tirofiban (Figure 6a). The top ranked result was 
the compound RCSI_00000319 (Figure 6b). The overlapping conformations were calculated using 
MOE (CCG), and show surprisingly good alignment with the key pharmacophore features in Tirofiban 
(Figure 6c). The compound „319‟ is part of the MA01 scaffold group (Scheme 1), with the diketone (K) 
option K01 and pyrazole X02 option used to build the azole ring, while the aldehyde used contributes 
major part of the molecule, the phenoxy-propane-dimethylamine. Further derivatization is thus possible 
at each of these positions, offering the possibility of readily synthesizing novel anti-thrombotics. The 
authors envisage that the TIN database and server will find similar utility in converting substrates into 
novel drug leads.  
  
CONCLUSIONS 
We have produced a virtual combinatorial library of 28 million molecules that are all theoretically 
synthetically feasible. The chemistry involved in synthesizing each of the keywords is well established 
and previously published. The databases are freely available and can be downloaded either (i) in their 
entirety, (ii) as 10% diversity subsets, (iii) as drug-like molecule subsets obeying Lipinski's Rule-of-
Five, (iv) as lead-like molecule subsets, or (v) as subsets defined by the core scaffold molecule.  
Furthermore, we have created an online search interface that allows users to draw input molecules for 
substructure or similarity searching of the full database. The 2-dimensional search function can also be 
accessed using 'TIN' codes of molecules that exist in the database. Thus users can find structural 
analogues of hit molecules found using TIN, such as the diversity or drug-like subsets.   
This facility will allow users to rapidly convert lead molecules into synthetically feasible compounds 
for synthesis and in vitro testing. Once hit compounds are identified, the variability inherent in the 
multicomponent synthesis methods will allow for relatively rapid synthesis of a wide range of 
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derivatives, which can then be used in repeating cycles of drug discovery. Further scaffold hopping is 
available using 2D searching (substructure/similarity) of the full database. The TIN database can be used 
in conjunction with the extremely versatile ZINC database of commercially available compounds.
7
 Lead 
molecules found using virtual screening of the ZINC compound library that are purchased and tested in 
vitro, can then be converted into synthetically feasible analogues using the 2D search function in TIN. 
This will then give researchers access to chemical diversity beyond that of the finite commercially 
available compound library.    
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Figure 1: Summary of scaffolds enumerated in the TIN database.  
Substituent colors are explained in Schemes 1-12.  
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Figure 2: Histogram of TIN compounds by molecular weight.  
„Drug-like‟ compounds are depicted with red bars.   
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Figure 3: Histogram of TIN compounds by logP(o/w).  
„Drug-like‟ compounds are depicted with red bars.   
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Figure 4: Histogram of hydrogen-bond acceptors and donors.  
Hydrogen-bond acceptors are depicted with blue bars, while Hydrogen-bond donors are depicted with 
red bars.   
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Figure 5: Diversity of TIN compared to ZINC.  
11,000 compounds were randomly selected from the diversity subset of TIN and the Tanimoto 0.6 
subset of ZINC (purchasable compounds). Substructure fingerprints were analyzed in each compound 
using a 307 bit search. Each point in this logarithmic scatter plot thus corresponds to the number of 
compounds found to have at least one copy of the fingerprint in either the ZINC dataset (x-axis) or TIN 
dataset (y-axis). To allow graphical representation, “null” is represented by “0.1”.     
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` 
Figure 6: TIN search using Tirofiban.  
A schematic of the structure of Tirofiban bound to platelet integrin GPIIbIIIa (2VDM) is shown in (A), 
while that of the TIN hit result „319‟ is shown in (B). This shows that both ligands interact with residues 
Arg214, Ser123, Ala218 and the Mg2+ cation. The MOE ligand interactions color scheme is as follows: 
polar residues, pink; acidic, red ring; basic, blue ring; hydrophobic residues, green; solvent exposure, 
blue zone; H-bonds, dashed green lines.  
(B) 
(A) 
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Scheme 1: Synthesis and definition of scaffold MA01. 
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Scheme 2: Synthesis and definition of scaffold MA02. 
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Scheme 3: Synthesis and definition of scaffold MA03. 
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Scheme 4: Synthesis and definition of scaffold MA04. 
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Scheme 5: Synthesis and definition of scaffold MA05. 
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Scheme 6: Synthesis and definition of scaffold MA06. 
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Scheme 7: Synthesis and definition of scaffold MA07. 
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Scheme 8: Synthesis and definition of scaffold MA08. 
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Scheme 9: Synthesis and definition of scaffold MA11. 
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Scheme 10: Synthesis and definition of scaffold MA16. 
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Scheme 11: Synthesis and definition of scaffold MA20. 
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Scheme 12: Synthesis and definition of scaffold MA21. 
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TABLES.  
Table 1: Reactant component subsets. 
Type of R-group
† 
Abbreviation Reactive group 
SMARTS
‡
  
Leaving 
Group 
Leaving 
Group 
SMARTS

Number of 
Entries 
Aromatic Aldehyde Ald [CH](=O)c Aldehyde [CH](=O) 226 
Aromatic Alcohol Alch_aro [OH]C([!O])c Hydroxyl [OH] 120 
Aromatic Alcohol  Alch_aroH [OH]C([!O])c Hydrogen [H] 120 
Aliphatic Alcohol Alch_naro [OH]C([!O])C Hydroxyl [OH] 404 
Aliphatic Alcohol Alch_naroH [OH]C([!O])C Hydrogen [H] 404 
Secondary Aromatic Amine NHAmi_aroNH [NH]c Hydrogen [H] 112 
Primary Aromatic Amine NHAmi_aroNH2 [NH2]c Hydrogen [H] 386 
Secondary Aliphatic Amine NHAmi_naroNH [NH]C Hydrogen [H] 97 
Primary Aliphatic Amine NHAmi_naroNH2 [NH2]C Hydrogen [H] 142 
Aromatic Carboxylic Acid Ac_aro [CX3](=O)(O) c Carboxylic 
Acid 
C(=O)O 616 
Aliphatic Carboxylic Acid Ac_naro [CX3](=O) (O)C Carboxylic 
Acid 
C(=O)O 324 
†Selected molecules in the Sigma-Aldrich catalogue were classified into possible reactant subunits compatible with multicomponent chemistry. 
‡„Reactive Groups‟ were identified, but only a subset of this was removed (the „Leaving Group‟) in preparation for linking to scaffolds.  
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Table 2: Bioactive molecules with TIN scaffolds in the ChEMBL and PubChem databases. 
 
  TIN scaffold 
substructure 
Active 
compounds* 
Protein 
Targets 
ChEMBL 35 26 17 
PubChem 1368 11 1 
Total 1403 37 18 
*PubChem active compounds are defined as those which pass the PubChem filter “Active in any bioassay”. ChEMBL active compounds are those 
that show a result in any assay that is Activation/Inhibition (IC50, EC50, Ki) < 10000 nM or Max Inhibition, Activity, Recovery > 50%.  
 
 
 
 
 
 
 
 
 38 
SYNOPSIS TOC: 
 
 
TIN is a virtual combinatorial database enumeration of diversity-orientated multicomponent syntheses, 
containing over 28 million compound structures for searching or downloading. 
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